Court Grants Natera’s Request to Include Additional Patent in its Lawsuit Against NeoGenomics

Amended complaint asserts infringement of U.S. Patent Nos. ‘596 and ‘454 by the modified version of NeoGenomics’ RaDaR assay

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced an expansion of its patent infringement lawsuit against NeoGenomics, Inc. related to its RaDaR® tests.

On December 10, 2024, the District Court for the Middle District of North Carolina (“The District Court”) granted Natera’s request to include an additional patent in its ongoing lawsuit against NeoGenomics. Natera’s amended complaint now includes U.S. Patent No. 11,319,596, as well as U.S. Patent No. 11,530,454 as previously asserted in the complaint.

Natera asserts infringement of the ’596 and ’454 patents by the new version of NeoGenomics’ RaDaR® test, which tests for molecular residual disease. This follows a December 2023 preliminary injunction and September 2024 permanent injunction ordered by the District Court of NeoGenomics’ previous version of its RaDaR® test.

Natera is seeking full remedies against NeoGenomics’ current RaDaR® test offering, including injunctive relief.

About Natera

Natera^TM is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health, and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas and San Carlos, California. For more information, visit www.natera.com.

Forward-Looking Statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to developments in matters under dispute or litigation, or the scope of protection we establish and maintain for, and developments or disputes concerning, our intellectual property or other proprietary rights. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.